Aldeyra Therapeutics (ALDX) News Today $4.88 +0.02 (+0.41%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Verition Fund Management LLC Sells 186,297 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Verition Fund Management LLC cut its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 84.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,530 shares of the biotechnology compDecember 17, 2024 | marketbeat.comShort Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3%Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,410,000 shares, a decline of 12.3% from the November 15th total of 3,890,000 shares. Based on an average daily volume of 476,600 shares, the short-interest ratio is currently 7.2 days.December 15, 2024 | marketbeat.comPositive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership with AbbVieDecember 10, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Grows Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Jacobs Levy Equity Management Inc. boosted its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 163.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 476,949 shares of the biotechnologyDecember 8, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest UpdateAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 3,890,000 shares, an increase of 6.0% from the October 31st total of 3,670,000 shares. Based on an average daily volume of 493,300 shares, the days-to-cover ratio is presently 7.9 days.December 3, 2024 | marketbeat.comAldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceDecember 3, 2024 | finance.yahoo.comEagle Asset Management Inc. Sells 132,053 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Eagle Asset Management Inc. cut its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 15.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 709,518 shares of the biotechnology company'sNovember 25, 2024 | marketbeat.comAldeyra Therapeutics Shares Up, FDA to Review New Drug ApplicationNovember 19, 2024 | marketwatch.comAldeyra Therapeutics Says FDA Accepts NDA For Reproxalap In Dry Eye DiseaseNovember 19, 2024 | markets.businessinsider.comAldeyra says FDA accepts reproxalap NDA, AbbVie deal expanded to $100MNovember 19, 2024 | markets.businessinsider.comAldeyra announces FDA acceptance of resubmitted reproxalap applicationNovember 19, 2024 | msn.comResearch Analysts Set Expectations for ALDX FY2024 EarningsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings estimates for Aldeyra Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post eaNovember 18, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Increase in Short InterestAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,670,000 shares, an increase of 7.9% from the October 15th total of 3,400,000 shares. Currently, 6.4% of the shares of the company are sold short. Based on an average trading volume of 443,400 shares, the days-to-cover ratio is presently 8.3 days.November 17, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for ALDX FY2028 Earnings?Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Research analysts at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechNovember 15, 2024 | marketbeat.comAldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 15, 2024 | finance.yahoo.comAldeyra Therapeutics’ Reproxalap: Promising Pipeline and Strategic Partnerships Justify Buy RatingNovember 9, 2024 | markets.businessinsider.comAldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingOctober 31, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by International Assets Investment Management LLCInternational Assets Investment Management LLC grew its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 397.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 287,287 shares of thOctober 30, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short InterestAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 3,400,000 shares, a growth of 13.3% from the September 30th total of 3,000,000 shares. Based on an average daily volume of 532,600 shares, the short-interest ratio is presently 6.4 days. Approximately 5.9% of the company's shares are short sold.October 29, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Dimensional Fund Advisors LP lowered its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 23.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 672,057 shares of the biotechnology company's stock after seOctober 12, 2024 | marketbeat.comAldeyra Therapeutics extends loan agreement termsOctober 4, 2024 | investing.comRenaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Renaissance Technologies LLC lowered its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 30.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 503,300 shares of the biotechnology company's sOctober 4, 2024 | marketbeat.comLexington biotech resubmits dry eye drug for FDA approval a year after rejectionOctober 3, 2024 | bizjournals.comAldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease TreatmentOctober 3, 2024 | marketwatch.comAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseOctober 3, 2024 | stockhouse.comAldeyra Therapeutics Reports Resubmission Of NDA For Topical Ocular ReproxalapOctober 3, 2024 | markets.businessinsider.comPerceptive Advisors LLC Acquires 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Perceptive Advisors LLC increased its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 7.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,275,851 shares of the biotechnology companySeptember 30, 2024 | marketbeat.comFederated Hermes Inc. Invests $1.76 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Federated Hermes Inc. purchased a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 531,221 shares of the biotechnology company's sSeptember 21, 2024 | marketbeat.comPFG Investments LLC Makes New $1.31 Million Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)PFG Investments LLC purchased a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 396,247 shares ofSeptember 10, 2024 | marketbeat.comAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comStocks in play: Mulvihill U.S. Health Care Enhanced Yield ETFAugust 31, 2024 | ca.finance.yahoo.comAldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case TheoryAugust 31, 2024 | msn.comAldeyra Therapeutics Has Data To Trigger AbbVie PartnershipAugust 28, 2024 | seekingalpha.comBuy Rating Affirmed for Immunic’s MS Treatment Vido with Unique Dual Mechanism and Promising Clinical DataAugust 27, 2024 | markets.businessinsider.comAldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%August 9, 2024 | msn.comBuy Recommendation for Aldeyra Therapeutics Amid Positive Phase 3 Results for ReproxalapAugust 9, 2024 | markets.businessinsider.comAldeyra climbs after late-stage success for dry eye disease therapyAugust 9, 2024 | msn.comAldeyra Therapeutics' (ALDX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a report on Friday.August 9, 2024 | marketbeat.comAldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease TreatmentAugust 8, 2024 | marketwatch.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) to Post Q4 2024 Earnings of $1.38 Per Share, Leerink Partnrs ForecastsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities researchers at Leerink Partnrs cut their Q4 2024 earnings estimates for Aldeyra Therapeutics in a report released on Monday, August 5th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earningAugust 8, 2024 | marketbeat.comAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapAugust 8, 2024 | finance.yahoo.comAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapAugust 7, 2024 | finance.yahoo.comBuy Rating on Aldeyra Therapeutics Backed by Strong Drug Pipeline and Lead Candidate’s Market PotentialAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aldeyra Therapeutics Amid Promising Drug Trials and Broad RASP Platform ProspectsAugust 3, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Invests $585,000 in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Jacobs Levy Equity Management Inc. bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 178,919 shares of the biotechnology company's stock, valued aAugust 3, 2024 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday.August 2, 2024 | marketbeat.comOwning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),July 31, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Growth in Short InterestAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 2,710,000 shares, a growth of 6.7% from the June 30th total of 2,540,000 shares. Based on an average daily trading volume, of 343,200 shares, the short-interest ratio is presently 7.9 days.July 30, 2024 | marketbeat.comAcadian Asset Management LLC Increases Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Acadian Asset Management LLC lifted its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 106.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,449 shares of the biotecJuly 25, 2024 | marketbeat.comFY2025 EPS Estimates for Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Reduced by Leerink PartnrsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research report issued on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology companJuly 11, 2024 | marketbeat.com Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. ALDX Media Mentions By Week ALDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALDX News Sentiment▼1.800.60▲Average Medical News Sentiment ALDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALDX Articles This Week▼22▲ALDX Articles Average Week Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CALT News Today SPRY News Today ANIP News Today SNDX News Today INVA News Today ELVN News Today RCKT News Today BCYC News Today OPK News Today AVDL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALDX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALDX Stock Alerts